CD19 and B-cell acute lymphoblastic leukemia: The success of adoptive immunotherapy using anti-CD19 chimeric antigen receptor (CAR)-expressing T cells to treat B cell acute lymphoblastic leukemia (B-ALL), though remarkable, is limited by a considerable number of relapses attributed to antigen loss.1